rise
zika
viru
zikv
unusu
clinic
manifest
provid
ground
specul
debat
clinic
sever
secondari
dengu
viru
denv
infect
associ
antibodydepend
enhanc
ade
recent
suggest
previou
exposur
denv
may
worsen
zikv
clinic
outcom
opinion
articl
analyz
relationship
among
differ
flavivirus
ade
discuss
new
evid
obtain
nonhuman
primat
human
cohort
demonstr
correl
ade
zikv
infect
occur
presenc
preexist
denv
immun
propos
redefinit
ade
context
complex
immunolog
flaviviru
interact
provid
object
perspect
translat
vitro
vivo
observ
clinic
set
tale
two
virus
heterolog
flaviviru
immun
enhanc
zika
diseas
carlo
sariol
mauricio
l
nogueira
niko
vasilaki
rise
zika
viru
zikv
unusu
clinic
manifest
provid
ground
specul
debat
clinic
sever
secondari
dengu
viru
denv
infect
associ
antibodydepend
enhanc
ade
recent
suggest
previou
exposur
denv
may
worsen
zikv
clinic
outcom
opinion
articl
analyz
relationship
among
differ
flavivirus
ade
discuss
new
evid
obtain
nonhuman
primat
human
cohort
demonstr
correl
ade
zikv
infect
occur
presenc
preexist
denv
immun
propos
redefinit
ade
context
complex
immunolog
flaviviru
interact
provid
object
perspect
translat
vitro
vivo
observ
clinic
set
rise
obscur
year
discoveri
zikv
caus
first
major
human
epidem
feder
state
micronesia
follow
major
pandem
introduct
brazil
sometim
current
indigen
mosquitoborn
zikv
transmiss
confirm
countri
territori
americasappendix
introduct
spread
zikv
america
mark
appear
sever
advers
outcom
fetal
loss
congenit
zika
syndrom
cz
see
glossari
syndrom
gb
rare
case
encephalopathi
meningoenceph
myeliti
uveiti
sever
thrombocytopenia
sever
hypothes
put
forward
explain
unpreced
observ
pathogen
zikv
infect
america
includ
prior
heterolog
flaviviru
infect
virul
viru
host
genet
environment
factor
among
other
analog
antibodydepend
enhanc
ade
secondari
denv
exposur
scientif
commun
hypothes
zikv
infect
follow
previou
denv
infect
may
result
increas
zikv
pathogenesi
exampl
cz
gb
america
ade
vitro
consid
common
experiment
phenomenon
uncertain
clinic
relev
demonstr
mani
virus
alphavirus
rabi
other
without
evid
worsen
diseas
secondari
infect
mice
human
popul
precis
ade
definit
specif
describ
experiment
find
fact
vitro
assay
immun
sera
patient
expos
varieti
differ
flavivirus
includ
yellow
fever
japanes
enceph
virus
also
enhanc
denv
infect
even
homotyp
serotyp
respons
past
denv
infect
induc
ade
denv
serum
dilut
subneutr
concentr
howev
contrast
ade
describ
virus
ade
denv
vivo
commonli
associ
wors
clinic
outcom
secondari
denv
infect
result
dramat
trend
zika
viru
zikv
caus
atyp
clinic
manifest
area
previou
exposur
flavirus
differ
denguezikv
crossreact
antibodi
neutral
enhanc
zikv
vitro
percentag
dengu
immun
serum
neutral
zikv
low
antibodydepend
enhanc
ade
zikv
dengu
west
nile
immun
sera
shown
vitro
induc
immunosuppress
mice
dengu
west
nile
immun
sera
ade
zikv
previou
dengu
immun
detect
nonhuman
primat
ade
zikv
document
human
cohort
previous
expos
dengu
ade
need
redefin
context
clinic
outcom
vitro
experiment
result
small
anim
need
care
weigh
translat
result
human
prospect
epidemiolog
clinic
studi
need
reassur
previou
exposur
dengu
flavivirus
increas
pathogenesi
zikv
clinic
impair
along
cytokin
storm
character
increas
interferong
ifng
ifna
vascular
endotheli
growth
factor
vegf
combin
tumor
necrosi
factora
tnfa
indic
poor
prognost
outcom
figur
ade
relat
flavivirus
seen
singl
biolog
process
virusantibodi
interact
defin
ade
context
pathogenesi
usual
read
outcom
biolog
process
impli
clinic
consequ
includ
clinic
laboratori
evid
impair
way
ade
would
defin
common
experiment
vitro
phenomenon
rare
vivo
occurr
lead
worsen
clinic
present
usual
associ
hemodynam
chang
increas
viremia
proinflamatori
cytokin
profil
detect
laboratori
alter
debat
whether
zikv
ade
flaviviru
immun
serum
recent
increas
result
show
increas
zikv
pathogenesi
mous
model
use
model
bardina
et
al
show
administ
denv
west
nile
viru
wnv
immun
serum
intraperiton
appropri
concentr
zikv
infect
result
fever
weight
loss
increas
mortal
compar
anim
administ
serum
individu
howev
result
howev
follow
fact
might
anticip
unlikelihood
denvinduc
zikv
ade
defin
human
epidemiolog
clinic
evid
denv
ade
close
relat
flaviviru
virus
ii
introduct
western
hemispher
zikv
continu
circul
flavivirusendem
area
africa
southeast
asia
increas
zikv
pathogenesi
report
locat
iii
heterolog
flaviviru
immun
includ
sequenc
infect
occur
differ
denv
serotyp
nhp
natur
host
sylvat
transmiss
cycl
support
replic
denv
zikv
mani
year
nhp
use
surrog
human
infect
order
understand
denv
pathogenesi
test
vaccin
immunogen
efficaci
recent
zikv
replic
pathogenesi
past
denv
ade
term
viral
replic
enhanc
also
proven
nhp
secondari
denv
infect
denv
passiv
administr
optim
dilut
human
denvimmun
serum
anim
use
specif
concentr
monoclon
antibodi
addit
use
studi
denv
pathogenesi
nhp
good
model
predict
behavior
differ
denv
vaccin
human
character
specif
denv
neutral
antibodi
also
occur
natur
human
popul
plausibl
anticip
data
zikv
pathogenesi
nhp
also
reproduc
predict
happen
human
recent
studi
use
limit
number
anim
pantoja
et
al
unabl
show
ade
zikv
denv
immun
macaqu
howev
result
show
previou
immun
denv
abl
modul
innat
cellular
immun
respons
zikv
tendenc
lower
averag
zikv
viremia
day
limit
increas
liver
enzym
induc
signific
increas
plasma
perforin
evid
increas
cytotox
cell
activ
cellular
immun
respons
nhp
support
recent
result
human
sampl
show
prior
denv
infect
lead
stronger
faster
respons
zikv
term
cell
respons
thu
provid
evid
biolog
outcom
coincid
report
pantoja
et
al
studi
ade
human
cohort
publish
terzian
et
al
evalu
cohort
zikvinfect
patient
look
previou
denv
exposur
relationship
viral
load
cytokin
profil
clinic
symptom
despit
suggest
vitro
studi
ade
could
occur
denvprim
zikvinfect
patient
author
found
evid
presenc
denv
antibodi
chang
outcom
zikv
infect
test
paramet
collect
observ
nhp
human
cohort
strongli
suggest
previou
exposur
denv
deleteri
summari
data
nhp
human
sever
serolog
studi
support
suggest
zikv
may
enhanc
vivo
previou
exposur
denv
hand
experiment
line
evid
address
ade
denv
induc
zikvimmun
serum
expect
shown
differ
degre
vitro
vivo
increas
denv
replic
pathogenesi
respect
recent
georg
et
al
report
infect
denv
short
period
exposur
zikv
enhanc
denv
infect
nhp
interest
report
expect
zikvinduc
denv
crossreact
antibodi
induc
earli
infect
may
either
neutral
effect
denv
infect
outcom
case
report
confirm
need
larg
studi
nhp
epidemiolog
data
human
popul
expos
zikv
recent
epidem
lastli
infer
deriv
vitro
experi
immunolog
modifi
anim
need
care
assess
due
impact
approach
zikv
denv
vaccin
therapeut
current
develop
role
time
interv
primari
denv
subsequ
zikv
infect
antibodi
cell
immun
respons
scenario
compar
zikv
infect
follow
two
denv
flaviviru
infect
time
infect
impact
clinic
outcom
recent
zikv
epidem
substanti
popul
zikvpositivedenvneg
peopl
risk
wors
clinic
present
partial
protect
denv
effect
zikv
compon
effect
denv
vaccin
current
clinic
trial
one
licens
countri
suscept
confer
popul
denv
zikv
vaccin
subsequ
heterogon
natur
infect
virus
